Teclistamab significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients with 1-3 prior therapies, achieving 69.8% 18-month progression-free survival.
- 19 cites
Multiple Myeloma Research and Treatments
Moving in Blood, New England Journal of Medicine.
- Moved this week
- 2
Rebuilt
Latest in Multiple Myeloma Research and Treatments
Newest first · last 60 days
Menin-MLL inhibitors increase JUND activity in MLL-rearranged leukemic cells, contributing to tumor growth and therapy resistance.
- Open access
Degrading NSD2 with a targeted ligand degrader reverses oncogenic chromatin changes and improves survival in t(4;14) multiple myeloma models.
Fibrocytes are the main collagen-producing cells in JAK2V617F-mutated myelofibrosis, accounting for nearly two-thirds of collagen production in the bone marrow.
- Open access
PKMYT1 inhibition induces DNA damage and cell death specifically in del(17p) multiple myeloma cells, offering a targeted therapeutic approach.
Epigenetic plasticity driven by genomic and cytogenetic changes enables therapy resistance and disease progression in multiple myeloma, with nearly 900 patient samples revealing key transitions.
- Open access
Tambotatug pelitecan significantly improves survival and response rates in relapsed small-cell lung cancer compared to topotecan, with fewer severe adverse events.
Elevated NF-κB activity in CD4 CAR-T cells predicts durable responses and improved survival in multiple myeloma patients treated with ide-cel.
Arlocabtagene autoleucel achieves an 87% overall response rate with durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.
- Open access
- 5 cites
Loss of DNA methylation in multiple myeloma leads to variable LINE-1 activation, with high L1 activity linked to increased proliferation and altered gene expression.
Mezigdomide reverses T-cell exhaustion by degrading IKZF1/IKZF3, restoring cytokine production and enhancing target cell killing in multiple myeloma.
- Open access
- 2 cites
Anti-BCMA/GPRC5D bispecific CAR T cells achieved a 97% overall response rate in patients with relapsed or refractory multiple myeloma with extraosseous extramedullary disease.
- Open access
Talquetamab combined with daratumumab and pomalidomide significantly prolongs progression-free survival in relapsed or refractory multiple myeloma, with 24-month estimates over 81%.
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4